Literature DB >> 21278823

AIs: implications for fractures in perimenopausal women with breast cancer.

Beatrice J Edwards1, Athena Samaras, June M McKoy, Simone Boyle, Charles L Bennett.   

Abstract

Entities:  

Year:  2008        PMID： 21278823      PMCID： PMC3028269          DOI： 10.1016/s1548-5315(11)70528-9

Source DB:  PubMed          Journal:  Community Oncol        ISSN： 1548-5315


× No keyword cloud information.
  6 in total

Review 1.  Aromatase inhibitors and bone health in women with breast cancer.

Authors:  Amy Jo Chien; Paul E Goss
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  NCCN Task Force Report: Bone Health and Cancer Care.

Authors:  Richard L Theriault; J Sybil Biermann; Elizabeth Brown; Adam Brufsky; Laurence Demers; Ravinder K Grewal; Theresa Guise; Rebecca Jackson; Kevin McEnery; Donald Podoloff; Peter Ravdin; Charles L Shapiro; Matthew Smith; Catherine H Van Poznak
Journal:  J Natl Compr Canc Netw       Date:  2006-05       Impact factor: 11.908

3.  Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.

Authors:  Betty A Mincey; Mei Sheng Duh; Simu K Thomas; Erick Moyneur; Maryna Marynchencko; Simone Peart Boyce; David Mallett; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2006-06       Impact factor: 3.225

Review 4.  Long-term effects of aromatase inhibitors on bone.

Authors:  Richard Eastell; Rosemary Hannon
Journal:  J Steroid Biochem Mol Biol       Date:  2005-05       Impact factor: 4.292

Review 5.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Rowan T Chlebowski; James N Ingle; Stephen B Edge; Eleftherios P Mamounas; Julie Gralow; Lori J Goldstein; Kathleen I Pritchard; Susan Braun; Melody A Cobleigh; Amy S Langer; Judy Perotti; Trevor J Powles; Timothy J Whelan; George P Browman
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

6.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

Authors:  M Baum; A Buzdar; J Cuzick; J Forbes; J Houghton; A Howell; T Sahmoud
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.